Dyameo raises 3 million euros for a probe that reads tumor margins during surgery

MedDevice Startups Staff · Oct 28 · 2 min read · Via Dealroom

Dyameo has raised 3 million euros to bring TempoTouch to market. Medevice Capital and NACO returned to the round. Bpifrance Amorçage Industriel, OBRATORI and Estellior Capital came in new, alongside French entrepreneurs the company did not name.

The system clips patented reagent capsules onto a probe linked to an optical fiber. A reader unit tells the surgeon whether the edge of the removed tissue still carries cancer cells. Dyameo is going after lung, head and neck, and skin cancers first. Seven people work on it in Limoges.

The money pays for higher production of the probe and its capsules. Dyameo also plans to hire a sales team and reach cancer surgery centers in France and abroad. The company is working toward CE marking and the device is not approved for routine use. No published trial has yet shown it improves patient outcomes.

Intraoperative margin assessment has a long graveyard of devices that read beautifully on a bench and stall once a surgeon has to use one under time pressure. The consumable capsule is the part of this model worth watching, because it is what turns a one-time probe sale into recurring revenue.

Questions & Answers

How much did Dyameo raise and who invested?

Dyameo raised 3 million euros, announced on October 28, 2026. Returning investors Medevice Capital and NACO were joined by Bpifrance Amorçage Industriel, OBRATORI and Estellior Capital, plus unnamed French entrepreneurs.

What does Dyameo's TempoTouch device do?

TempoTouch checks during surgery whether the edges of removed tissue are free of cancer cells, so a surgeon knows whether the tumor was fully excised. Patented reagent capsules clip onto a probe linked to an optical fiber, and a reader unit displays the result.

Does Dyameo's TempoTouch have regulatory approval?

No. As of October 28, 2026, Dyameo was targeting CE marking for TempoTouch and the device was not approved for routine use. The company has not published trial results showing improved patient outcomes.

← Back to Fundraising